Bill & Melinda Gates Foundation Invests $5 Million To Fight Cancer — Other Startups On Same Track
Benzinga· 1 day agoFoundation is known for spending big money to fight infectious diseases in developing countries....
...Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial...in Non-Small Cell Lung ...
Benzinga· 4 days ago(Candel or the Company) CADL, a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer ...
...Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus...
FOX 23 News Albany· 2 days agoPlanned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically ...
A Framework to Evaluate the Clinical Utility of Multicancer Early Detection (MCED) Technologies:...
Morningstar· 2 days agoDetection (MCED) Consortium releases a clinical utility framework to assist decision-makers in making judgments about the benefits and risks of MCED technologies. WASHINGTON, Sept. 28, 2023 ...
Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints
Morningstar· 1 week agoThe companies on Friday said the study that combined Merck's blockbuster cancer drug Keytruda with Astellas' and Seagen's Padcev versus chemotherapy met its dual primary endpoints ...
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual...
Benzinga· 3 days agoOne clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
WWTI Watertown· 1 week agocancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging...
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer - Icecure...
Benzinga· 1 week agoFood and Drug Administration ("FDA") has at this time denied the Company's De Novo Classification request for breast cancer which was ...
Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise (NASDAQ:CYT)
Seeking Alpha· 2 weeks agoCyteir (NASDAQ:CYT) is a developer of cancer therapeutics. Lead candidate CYT-0851 is an orally bioavailable small molecule inhibitor of monocarboxylate transporters targeting ...
Cancer experts demand action to end ongoing drug shortage: ‘People’s lives are really at stake’ -...
7 News Miami· 2 weeks agoThe American Association for Cancer Research, in its annual cancer progress report released Wednesday, highlighted the recent improvements that the United ...
Yahoo Web Search
Trending Now
